Diethylnitrosamine 으로 유도된 간암 발생과정 에서 Nrf2의 역할 by 노황지
 
 
저 시-비 리- 경 지 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적 된 허락조건
 명확하게 나타내어야 합니다.  
l 저 터  허가를 면 러한 조건들  적 되지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 목적  할 수 없습니다. 

























The oncogenic potential of Nrf2 in 
diethylnitrosamine-induced murine 
hepatocarcinogenesis 
Diethylnitrosamine 으로 유도된 간암 발생과정 에서 
Nrf2의 역할 
지도교수 서영준 
이 논문을 약학박사 학위논문으로 제출함 




NGO HOANG KIEU CHI 
 
NGO HOANG KIEU CHI 의 약학박사학위논문을 인준함 
2017 년 8 월 
위 원 장                                   (인) 
부위원장                                   (인) 
위    원                                    (인) 
위    원                                    (인) 









HOANG KIEU CHI NGO 
A dissertation submitted to the College of Pharmacy in partial 
fulfillment of the requirements for the degree of 
DOCTOR OF PHYLOSOPHY 
(Major: Pharmaceutical Bioscience) 
Seoul National University 




Advisory Committee Chair, Professor Jung Weon Lee 
 
Advisory Committee Vice-Chair, Professor Marc Francois Diederich 
 
Advisory Committee, Professor Kyu-Won Kim 
 
Advisory Committee, Professor Hye-Kyung Na 
 










Ngo Hoang Kieu Chi 
Under the supervision of professor Young-Joon Surh 
Division of Pharmaceutical Bioscience 
College of Pharmacy 
The Graduate School 
Seoul National University 
 
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-
related deaths, and is phenotypically and genetically heterogeneous. 
Nuclear factor-erythroid 2-related factor 2 (Nrf2, also known as 
Nfe2l2) is a transcription factor that regulates the expression of a 
battery of genes encoding phase II carcinogen detoxifying enzymes and 
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other cytoprotective proteins, hence being considered a prominent 
target for liver cancer chemoprevention. However, here I unexpectedly 
found that Nrf2 knockout mice resisted diethylnitrosamine (DEN)-
induced hepatocarcinogenesis without impairment in either metabolic 
activation of DEN by cytochrome P450 2E1 (Cyp2e1) or hepatic 
vasculature. In the liver tumors, there was enhanced expression, nuclear 
translocation, and transcriptional activity of Nrf2. The overactivated 
Nrf2 was noticed to be required for hepatoma growth during DEN-
induced murine HCC. Following DEN treatment, genetic disruption of 
Nrf2 led to a decrease in the expression levels of a transporter involved 
in glucose uptake and pentose phosphate pathway (PPP)-related 
enzymes, whose depletion is reportedly associated with amelioration of 
HCC. Of note, alterations in the domain binding to its endogenous 
inhibitor Kelch-like ECH-associated protein 1 (Keap1) likely accounted 
for the enhanced activity of Nrf2. Additionally, HCC patients bearing 
activating mutations in Nrf2 had shorter overall survival compared with 
their cohort. These findings suggest that Nrf2 is a bona fide liver cancer 
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1. Keap1/Nrf2/ARE axis 
Environmental carcinogens are normally inert chemically and lack 
ability to modify DNA unless they are converted to reactive species by 
xenobiotic-metabolizing enzymes (1,2). Biologically reactive 
metabolites of carcinogens are electrophilic, in general, and hence able 
to interact covalently with DNA. The resulting DNA adduct formation 
can cause mutations and consequently carcinogenesis (1,2). To prevent 
such deleterious effects of chemical carcinogens, the cell mounts 
various defense mechanisms, such as blockade of the formation of 
reactive intermediates or stimulation of detoxification through 
conjugation reaction catalyzed by phase II drug-metabolizing enzymes 
(3). It is important to note that the majority of genes encoding phase II 
carcinogen detoxifying enzymes and related cytoprotective proteins 
contain the consensus sequence 5’-TGCTGAG/CTCAT/C-3’ named the 
antioxidant responsive element (4) or electrophile responsive element 
(EpRE) in their 5’-flanking regions (5,6). 
Nrf2 was first characterized as a transcriptional activator that 
binds to a tandem repeat sequence named NF-E2 sequence (5’-
TGCTGAG/CTCAT/C-3’; ref. (7). Subsequently, Itoh et al. recognized 
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the similarity between the NF-E2 binding sequence and the antioxidant 
response element sequence which is identified within the regulatory 
regions of many antioxidant and phase II carcinogen detoxifying 
enzymes (8). Hence, it has been widely accepted that activating Nrf2 
protects cells from the DNA-damaging effects of reactive oxygen 
species (ROS) and electrophilic metabolites of carcinogens. Moreover, 
use of Nrf2 activators has been considered a beneficial therapeutic 
approach in the management of disorders associated with the 
accumulation of oxidative stress, such as diabetic complications (9), 
cardiovascular diseases (10), neurodegenerative disorders (11), and 
cancer (12).  
Human Nrf2 protein is composed of 605 amino acids with seven 
conserved regions named Nrf2-erythroid cell-derived protein with CNC 
homology (ECH) domains (Neh) (13) which are distributed along the 
coding region (Fig. 1A). The Neh1 domain is located in the C-terminal 
half of Nrf2 and contains the CNC homology region and a basic-leucin 
zipper domain, which allows Nrf2 to form a heterodimer complex with 
small Maf and then bind to the ARE region in target DNAs (13). The 
small Maf subunit possesses a leucin zipper domain required for 
homodimer or heterodimer complex formation with other bZip 
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transcription factors. Maf can recognize Maf recognition element 
(MARE), which strikingly resembles ARE consensus sequence, but 
Maf lacks canonical transcriptional activation domains, hence requiring 
a CNC factor for the activation function of the heterodimers (14). The 
proximal amino terminal Neh2 domain negatively regulates Nrf2 
through binding of its DLG and ETGE motifs to Keap1 (14,15). The 
Neh3 domain in the C terminus of Nrf2 allows Nrf2 to interact with a 
chromo-ATPase/helicase DNA binding protein CHD6, which functions 
as an Nrf2 transcriptional activator (16). Neh4 and Neh5 adjacent to 
Neh2 cooperatively bind to cAMP responsive element binding protein 
(CREBP) binding protein (CBP), which plays an essential role as a 
coactivator of many transcription factors, to attain the maximal 
transcriptional activity of Nrf2. CBP-interacting motif in Neh5 is 
conserved among other members in CNC family, whereas, CBP-
binding motif in Neh4 is rather new to that of others in the same family 
(17). Neh6 contains two phosphorylation-dependent destruction motifs 
(DSGIS and DSAPGS) recognized by beta-transducin repeats-
containing proteins (β-TrCP) of Skp-Cullin1-F-box protein (SCF) E3 
ubiquitin ligase complex. Phosphorylation of a Ser cluster in DSGIS 
motif by glycogen synthase kinase-3 beta (GSK-3β) facilitates the 
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recognition of Nrf2 by β-TrCP and promotes its ubiquination followed 
by a rapid turnover (18-20). An Neh7 domain through which retinoic X 
receptor alpha (RXRα) binds to and subsequently suppresses the 
transcriptional activation of Nrf2 was then identified in 2013 (21). 
Under a physiological condition, Nrf2 is sequestered in the cytoplasm 
due to its binding to Keap1. Keap1 contains two canonical protein 
interaction motifs: a Broad-complex C, Tramtrack, and Bric-a-brac 
(BTB) and a double glycine repeat (DGR) or Kelch repeat respectively 
located in the middle and carboxy terminus, typical of Drosophila 
cytoskeleton binding protein Kelch (14). Two additional domains of 
Keap1 include interventing region (IVR) and C-terminal region (CTR) 
(22,23) (Fig. 1B). Each Keap1 molecule uses a C-terminal Kelch 
domain (DGR) to interact separately with two Keap1 binding motifs in 
the Neh2 domain of Nrf2 (15). The BTB domain allows two Nrf2-
bound Keap1 molecules to form a homodimer (24), which serves as an 
adaptor bridging Nrf2 to Cullin3-associated E3 ubiquitin ligase 
complex (25,26). The binding of Nrf2 to Cul3 anchored by Keap1 
promotes ubiquitin conjugation of lysine residues in the Neh2 domain 
and therefore marking Nrf2 for degradation by 26 S proteasomes 
(25,26). Due to the constant exposure of mammalian cells to oxidative 
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stresses, cystine residues, particularly C273 and C288 residues, in IVR 
domain in Keap1 would undergo oxidation to form intermolecular 
disulfide bonds (most likely one C273 of one monomer and C288 of the 
other), thus covalently linking two monomers of Keap1. Such 
intermolecular disulfide linkage subsequently introduces an increase in 
the distance between the two DGR domains of two Keap1 molecules, 
which possibly dislodges the weaker binding between DGR of the 
Kelch domain and the DLG motif in Nrf2. Consequently, the modified 
Keap1 is no longer able to sequester newly synthesized Nrf2 (Fig. 1C, 
left), allowing it to translocate into the nucleus and enhance the 
expression of phase II enzymes for the clearance or inactivation of the 
ROS or electrophilic species (15,22,23). Alterations in DLG and ETGE 




















Figure 1. Structures explaining the negative regulation of Nrf2 by 
Keap1. (A) Structure of Nrf2. The positions of seven Nrf2-ECH 
homology  domains are shown. DLG and ETGE motifs by which Nrf2 
associates with Keap1 are highlighted. (B) Structure of Keap1. BTB: 
Broad-complex C, Tramtrack, and Bric-a-brac; IVR: intervening 
region; DGR: double glycine rich; CTR: Carboxyl terminal region. (C) 
Distortion of Nrf2-Keap1 association. Middle: one Nrf2 molecule use 
low-affinity DLG and high-affinity ETGF motifs to associate with two 
Keap1 molecules through its DGR domain. BTB domain in Keap1 
allows two Keap1 molecule to form a homodimer and through the same 
BTB domain recruit Cullin (Cul) 3 to ubiquitinate Nrf2 at lysine 
residues clustered between DLG and ETGE, finally subjecting Nrf2 to 
26S proteasomal degradation. Left: Any genetically changes in either 
DLG or ETGE motif would lead to the dissociation of Keap1-Nrf2 
binding. Right: Disulfide bonds formed due to the reaction of oxidants 
with reactive thiol groups to cross link two Keap1 molecules, 






Paradoxically, cancer cells hijack Nrf2 signaling, and Nrf2 
activators turn out to accelerate tumor progression and metastasis in 
mice (27-29). In this respect, mounting evidence supports that tumors 
are addicted to Nrf2 signaling (30,31) and some Nrf2-dependent 
signaling pathways are linked to clinical aggressiveness of cancer cells 
(31,32). Overexpression/overactivation of Nrf2 frequently observed in 
various types of cancer is strongly associated with a poor clinical 
outcome (33,34). Like the majority of other transcription factors, Nrf2 
has an inhibitory partner. Thus, Nrf2 forms an inactive complex with 
Kelch ECH associated protein (Keap) 1 in the cytoplasm (13). Notably, 
mutations in a region encoding Keap1 binding domain of Nrf2 are 
commonly observed in cancer, which also contributes to the sustained 
overactivation of Nrf2 (35). 
 
2. Nrf2 mutation in cancer 
The first study demonstrating the overactivation of Nrf2 in cancer was 
reported in 2004 by Ikeda et at (36). In the study, mRNA levels of Nrf2 
and placental glutathione S-transferase (GST-P), an Nrf2-regulated 
phase II-detoxifying enzyme that is expressed in cancerous but not 
normal tissue, were highly elevated in hyperplastic rat liver tissue and 
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during the course of hepatocellular carcinoma development. The Nrf2-
dependent defense response was also found to be activated in various 
types of cancer including head and neck squamous cell carcinoma (37), 
and lung cancer (38). Subsequently, it came to be recognized that the 
Keap1-Nrf2 signaling pathway is largely dysregulated, which would 
account for the overactivation of Nrf2. Keap1 somatic mutations 
accompanied by loss of heterozygousity at the gene locus is common in 
non-small lung cancer, leading to inactivation and consequently the loss 
of Nrf2 repression by Keap1 (39,40). The reduction of inhibitory 
effects of Keap1 on Nrf2 activation in cancer could be ascribed to 
hypermethylation of CpG island in Keap1 promoter in lung cancer 
tissue and lung cancer cells (41). Moreover, gain-of-function of Nrf2 in 
cancer commonly arises from genetic alterations in Nrf2. Indeed, Nrf2 
is commonly found to be mutated in various types of cancer. The very 
first study by Shibata et al. uncovered frequent mutations in Nrf2 in 
lung cancer cell lines as well as in primary cancer tissue of lung and 
head and neck cancers (42). Nrf2 mutations which are mostly of 
somatic origin were subsequently identified in other types of cancer 
including oesophageal and skin cancer (43). Data provided by The 
Cancer Genome Atlas (TCGA) database (http://cancergenome.nih.gov/) 
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and publicly available at cBioportal (44,45) have uncovered that Nrf2 
mutations are common in primary tumors arising from approximately 
20 types of organs (Fig. 2A), which have been found to be correlated 
with its enhanced transcriptional activity (42,43). Among them, lung 
squamous cell carcinoma carries the highest frequency of Nrf2 
mutation (~19%), followed by head and neck squamous cell carcinoma 
(~10%) and esophageal adenocarcinoma (~8.5%). Mutations of Nrf2 
are rare in breast, thyroid and brain cancers (Fig. 2A). Of note, genetic 
alterations of Nrf2 are sorted into DNA amplification and mis-sense 
mutation with almost the same percentage (Fig. 2B). Substitution 
mutation accounts for most of mis-sense mutation, and substitutions are 
found all along the coding region of Nrf2. It is noticeable that mutations 
occurring with the highest frequency cluster in either DLG (D29, L30, 
G31, and R34) or ETGE (E79, T80, G81, and E82) motifs of Neh2 
domain (Fig. 2C). Genetic alterations in ETGE were experimentally 
shown to result in the failure in the recognition of Nrf2 by Keap1 
regardless of the absence of altered DLG, whereas changes in DLG 
without alterations in ETGE only affected the binding of DLG with 
Kelch but not that of wild-type ETGE and Kelch. However, mutations 
in DLG confer Nrf2 the resistance to ubiquitination, resulting in the 
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impairment of Keap1-directed proteasomal degradation of Nrf2 (42,46). 
By contrast, substitutions are rarely found in DNA binding domain of 
Nrf2 (known as bZIP-Maf or Neh1, Fig. 2C), which allows ETGE- or 
DLG- mutant Nrf2 to maintain its transcriptional activity. Consistently, 
data from cancer tissues carrying Nrf2 with aforementioned mutations 
unveiled that the transcription factor preferentially translocated into the 
nucleus and were dramatically more active than wild-type Nrf2 (42,43). 
Note that this represents constitutive activation of Nrf2 in an 
irreversible. Noticeably, the frequency of substitutions in the Neh6 
domain which in addition to the Neh2 domain negatively regulates Nrf2 
stability (47) is not distinctive (Fig. 1C). Hence, it is likely that cancer 
cells evolve to have substitutions exclusively clustered in Nrf2 hotspot 
regions coding for DLG and ETGE, which allows Nrf2 to bypass the 
suppression of Keap1, resulting in the overactivation of this 
transcription factor. The driving mechanism of this phenomenon 





Figure 2. Nrf2 is frequently mutated in various types of cancer. (A) 
Frequencies of Nrf2 mutations in many types of cancer. (B) 
Distribution of Nrf2 mutations with amplification and missense 
mutation occurring at almost the same frequency and accounting for 
most of Nrf2 genetic alterations. (C) Distribution of Nrf2 substitution 
mutations along the coding region of Nrf2 with the highest frequency 





PURPOSE OF THIS STUDY 
Hepatocellular carcinoma (HCC), which comprises approximately 90% 
of cases of liver malignancy, is the third leading cause of cancer-related 
mortality worldwide (48) and is associated with diverse etiologic 
factors, such as hepatitis B and C viral infection, chronic alcohol intake, 
and exposure to a variety of dietary and environmental chemical 
carcinogens (49). Recent progress in genomic analyses allows 
identification of several critical driver mutations and activating 
signaling pathways involved in HCC development (50,51). Somatic 
mutations in nuclear factor-erythroid 2-related factor 2 (Nrf2, also 
known as Nfe2l2) were also noticed through whole-genome sequencing 
of HCC patients (48,50). Additionally, somatic mutations in Nrf2 were 
noticed as an early molecular event in an experimental model of HCC 
in rodents (52). However, the biological significance of these changes 
in the context of Nrf2 involvement in hepatocellular carcinogenesis 
remained overlooked. Hence in this study, by utilizing Nrf2 knockout 
(KO) mice in a mouse model of HCC chemically induced by DEN, I 
aim to investigate the role of Nrf2 in hepatocarcinogenesis and to 




MATERIALS AND METHODS 
1. Animals 
Wild-type (WT) and Nrf2 KO mice on a C57BL6/129SV mixed 
background generated by the laboratory of Yuet Wai Kan as described 
previously were used in this study (53). Transgenic (Tg) mice carrying 
the core ARE sequence coupled to the human placental alkaline 
phosphatase (hPAP) gene (ARE-hPAP mice) were generously gifted by 
Dr. Jeffrey A. Johnson (University of Wisconsin-Madison, Madison, 
WI) (54). In brief, a core sequence ARE carried by 51-bp fragment of 
rat NAD(P)H:quinone oxidoreductase 1 (Nqo1) was inserted to a 
TATA-Inr minimal promoter of the heat-stable hPAP reporter construct. 
This construct was thereafter injected into fertilized oocytes that were 
then implanted into uteri of surrogate mothers. Resulting pups were 
identified by genotyping. Mice were maintained in a 12-hour dark-light 
cycle with the light cycle occurring from 7:00 AM to 19:00 PM and 
given ad libitum access to food and water. All animal experiments were 
approved by the Seoul National University Animal Care and Use 
committee (approval number: SNU 20140624-2).  
For genotyping, clipped mouse toes were incubated with a 
genotyping buffer containing 1% sodium dodecyl sulphate (SDS), 0.1 
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mol/L NaCl, 100 mmol/L EDTA, 50 mmol/L Tris (pH 8.0), and 1 
µg/µL proteinase K at 55
0
C overnight. On the next day, 5 mmol/L NaCl 
was added to remove cell debris. DNA was precipitated by incubating 
in cold 2-propanol at -20
0
C for 2 hours, and then washed with cold 
70 % ethanol. Six-hundred nanograms of DNA was used as a template 
for the genotyping PCR following a standard procedure. PCR primer 
sequences employed are presented in Table 1. Genomic Nrf2 (gNrf2) 
was also used as an internal control in genotyping ARE-hPAP mice. 
PCR products were separated on 2% agarose gels and visualized under 
imagequant
TM




2. DEN-induced hepatocellular carcinoma in mice 
At day 15 of age, male mice of each genotype (WT and Nrf2 KO, and 
ARE-hPAP mice) were given a single dose of 25 mg/kg DEN prepared 
in PBS (pH 7.4) by intraperitoneal (i.p.) injection, following the 
protocol described previously (55). Tumor burden was evaluated at 
indicated times during the course of experiments. Visible nodules (≥ 0.5 





3. Perfusion of the liver with a Trypan blue solution 
Perfusion was performed on 15-day-old WT and Nrf2 KO mice. Mouse 
liver portal vein was cannulated with a 25-gauge needle connected with 
a catheter. Subsequently, the inferior vena cava was cut, and the portal 
vein was perfused with PBS (pH 7.4), followed by a perfusion with a 
0.4% solution of trypan blue (Sigma) in PBS.  
 
4. Short-term treatment of animals with DEN 
Fifteen-day-old WT and Nrf2 KO mice were given a dose of 25 mg/kg 
DEN prepared in PBS (pH 7.4) by i.p. injection. Livers were isolated at 
indicated times and subjected to subsequent experiments.  
 
5. Hematoxylin and eosin staining  
Mice were perfused with PBS (pH 7.4). Livers were isolated, fixed in 
4% paraformaldehyde (PFA)/PBS overnight. After paraffin embedding 
and serial section (5 μm), hematoxylin and eosin (H&E) staining was 
performed.  
 
6. hPAP staining 
Paraffin-embedded tissue sections were deparaffinized by soaking 
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consecutively in xylene followed by a series of gradient ethanol (100 % 
x 2 times, 90 %, 80 %, and 70 %) and fixed again in 4% PFA/PBS (pH 
7.4), then incubated in PBS at 70 
0
C. Slides were thereafter washed in 
AP buffer (100 mmol/L Tris-HCl pH 9.5, 100 mmol/L NaCl, 50 
mmol/L MgCl2, 0.01% sodiumdeoxycholate, and 0.02% Nonidet-P40), 
and treated with 0.34 mg/ml nitroblue tetrazolium salt (NBT; Sigma) 
and 0.17 mg/ml 5-bromo-4-chloro-3-indolyl phosphate, toluidinnium 
salt (BCIP; Sigma) prepared in AP buffer for 18 hours at 37
0
C. 
Afterwards, slides were mounted with coverslips, and observed under a 
light microscope (Leica DM5000B; Leica Microsystems, Inc.). 
 
7. Immunohistological analysis 
At the indicated times, mice were perfused with PBS (pH 7.4), and 
livers were then isolated and fixed in 4% PFA/PBS overnight. After 
dehydration through a series of gradient sucrose (10% and 30% sucrose 
in PBS), the livers were immersed in optimal cutting temperature 
(OCT) embedding compound (Tissue-Tek) and subsequently sectioned 
at 5 µm thickness on a microtome (HM525; Thermo Scientific). 
Cryosections were washed briefly with PBS (pH 7.4) and then the 
nonspecific binding was blocked with a buffer containing 0.3% Triton 
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X-100 and 5% (v/v) donkey serum (Sigma) in PBS before being 
incubated with primary antibodies prepared in the blocking buffer at 
4
o
C in a humidified chamber overnight. On the next day, the slides 
were treated with Alexa 488 and 546 secondary antibodies (Molecular 
Probe, Invitrogen), followed by nuclear-counterstaining with 4',6-
diamidino-2-phenylindole (DAPI; Molecular Probe, Invitrogen). 
Afterwards, images were obtained under a confocal microscopy (LSM 
700; Carl Zeiss). 
 
8. Bromodeoxyuridine staining 
Fifteen-day-old WT and Nrf2 KO mice were given an i.p. dose of DEN 
(25 mg/kg) prepared in PBS. A single i.p. dose of 50 mg/kg 
bromodeoxyuridine (BrdU; Sigma) was administered to DEN-injected 
mice 2 hours before mice were sacrificed. Livers were isolated at 48 
hours after DEN injection. Paraffin-embedded liver sections were 
deparaffinized and subsequently denatured in a mild hydrochloric acid 
solution before stained with an antibody specific for BrdU. Signals 
were developed using the ABC staining kit and 3,3’-diaminobenzidine 
(DAB;Vector Laboratories). The sections were counter-stained with 
hematoxylin, mounted with coverslips, and visualized under a light 
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microscope (Leica DM5000B; Leica Microsystems, Inc.). 
 
9. Antibodies 
Antibodies used in this study and their sources were glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; sc-365062; Santa Cruz; 1:2,000), 
α-Tubulin (MU-121UC; Biogenex; 1:2,000), β-Actin (A2066; Sigma; 
1:2,000), Lamin B (sc-6216; Santa Cruz; 1:2000), Nrf2 (sc-722; Santa 
Cruz; 1:1000 for Western blotting and 1:200 for immunostaining), 
Nqo1 (Ab28947; Abcam; 1:2000), cyclin D1 (#2926; Cell Signaling 
Technology; 1:2000), proliferating cell nuclear antigen (PCNA; #2586; 
Cell Signaling Technology; 1:500), phosphogluconate dehydrogenase 
(Pgd; sc-398977; Santa Cruz; 1:2000), malic enzyme (Me) 1 (sc-
100569; Santa Cruz; 1:2000), cytochrome P450 2E1 (Cyp2e1; 
HPA009128; Sigma; 1:1000 for Western blotting and 1:200 for 
immunostaining), and  BrdU (ab1893; Abcam, USA; 1:200). 
 
10. Western blot analysis 
Liver tissue was lysed in lysis buffer [50 mmol/L Tris-Cl (pH 7.5), 150 
mmol/L NaCl, 1 mmol/L EDTA (pH 8.0), 1% NP-40, 0.25% 
deoxycholate, protease cocktail tablets]. In some experiments, 
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hypotonic [10 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic 
acid (pH 7.9), 1.5 mmol/L MgCl2, 10 mmol/L KCl, 0.5 mmol/L DTT 
and 0.2 mM PMSF] and hypertonic [20 mmol/L N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid (pH 7.9), 20% 
glycerol, 420 mmol/L NaCl, 1.5 mmol/L MgCl2, 0.2 mmol/L 
ethylenediaminetetraacetic acid (EDTA), 0.5 mmol/L DTT and 0.2 
mmol/L PMSF] lysis buffers were used for extraction of cytosolic and 
nuclear proteins. Protein concentrations were measured using Pierce 
BCA Protein Assay Kit (Thermo Scientific, USA). The lysates were 
then separated on 8% or 10% SDS-polyacrylamide gels and transferred 
to polyvinylidene difluoride (PVDF) membranes. Membranes were 
blotted with different anbitodies and visualized under an imagequant
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LAS 4000 (Fujifilm Life Science, Stamford, USA) for detection of 
indicated proteins. 
 
11. Reverse transcription-quantitative real-time polymerase chain 
reaction  
Total RNA was isolated from liver tissue using TRIzol
®
 (Invitrogen). 
RNA was then used to synthesize complementary DNA (cDNA) and 





 qPCR kit (Nanohelix) with Applied 
Biosystem 7500 Fast Real-Time PCR System (Applied Biosystem). 
The relative RNA expression levels were determined accoding to the 
comparative threshold cycle (Ct value) method. Gapdh was included as 
an internal control. The primers used in qPCR assay are listed in Table 
2.  
 
12. Cell culture and transfection 
HEK293T cells were obtained from ATCC in 2010. The cells were 
cultured in DMEM (Genedepot) supplemented with 10 % v/v FBS and 
100 units/mL penicillin and 100 µg/mL streptomycin (Gibco, 
Invitrogene) in a humidified atmosphere of 95% O2 and 5% CO2 in an 
incubator at 37
0
C and used within ten passages. Mycoplasma test was 
routinely performed using a BioMycoX® Mycoplasma PCR Detection 
Kit (CellSafe) to ensure that cells were negative for Mycoplasma 
contamination. As HEK293T cells are solely used as an expression 
system but not for cancer-related biological studies, they were not 
authenticated. The cells were transfected with indicated plasmids using 
transfection reagent polyethylenimine (PEI; Sigma) following 
manufacturer’s instructions. Twenty-four hours after transfection, the 
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cells were harvested for subsequent assays.  
 
13. Sequencing 
Total RNA was extracted from vehicle- or DEN-treated liver tissue and 
converted to cDNA using reverse transcriptase enzyme following the 
standard procedure. The cDNA region bearing exon 2 of murine Nrf2 
gene was amplified using PCR with HiPi Taq polymerase (Elpisbio). 
The PCR products were purified by QIAquick PCR Purification Kit 
(Qiagene), and sequenced by ABI PRISM 3130xl Genetic Analyzer 
(Applied Biosystems). Primers for sequencing are listed in Table 3. 
Mutations are defined and given in accordance to the numbering of 
amino acid in murine Nrf2 protein sequence (NCBI CCDS Database; 
gene number: NC_000068.7) 
 
14. Plasmids and site-directed mutagenesis  
A plasmid of pcDNA3.1-EGFP-C4-human NRF2 was obtained from 
Addgene (plasmid #21549, generated by Dr. Yue Xiong’s lab). For a 
murine Nrf2 expression vector, a plasmid of murine Nrf2 (AAV-MCS8-
Nrf2) was purchased from Addgene (plasmid #67636, generated by Dr. 
Connie Cepko’s lab). Various constructs of Nrf2 bearing point 
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mutations were generated using Muta-Direct Site Directed Mutagenesis 
Kit (iNtRON). A stop codon ATG was introduced to the murine Nrf2 
construct to halt the expression of Nrf2. Primer sequences used appear 
in Table 4. All plasmid clones were verified by DNA sequencing. 
 
15. Clinical data collection 
The cBioPortal for Cancer Genomics (http://www.cbioportal.org/) 
(44,45) is the main source of information. In total, data from 231 HCC 
cases provided by ASAN Medical Center (AMC) (56) and 356 HCC 
cases obtained from The Cancer Genome Atlas (TCGA) Research 
Network (http://cancergenome.nih.gov/) were collected and sorted into 
groups with WT or mutant Nrf2 before being subjected to Kaplan-
Meier survival analysis. Raw data are provided in Dataset 1. The 
statistical significance of differences between two groups was evaluated 
based on log-rank test. Data are presented as mean ± SEM. Data 
analyses were performed using Graphpad Prism (Version 6).  
 
16. Statistical analysis 
The statistical significance of differences between two groups was 
evaluated based on two-tailed Student t test. Statistical significance was 
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accepted at P < 0.05. 
*
P < 0.05, 
**
P < 0.01; 
***
P < 0.001; 
#
P < 0.0001. 
Data are presented as mean ± SEM. Data analyses were performed 
























Nrf2 deficiency abolishes hepatoma burden in mice treated with 
DEN 
To investigate the role of Nrf2 in liver tumorigenesis, I compared the 
development of HCC in WT and Nrf2 KO mice. Their genotype was 
verified by genotyping (Fig. 3A). Male mice of each phenotype were 
given a single i.p. injection of DEN at day 15 after birth following the 
protocol described previously (55). After 9 months, I noticed that all the 
WT mice treated with DEN developed hepatomas, whereas no tumors 





Figure 3. Nrf2 KO mice are resistant to DEN-induced 
hepatocarcinogenesis after 9 months of DEN treatment. (A) WT and 
Nrf2 KO male mice were identified by genotyping. (B) Male mice of 
each genotype (n = 7 mice per genotype) were given DEN at the 
postnatal day 15 and evaluated for tumor burden at the age of 9 months. 
Gross morphology of livers, the proportion of liver tumor-bearing mice, 
the number of tumors per mouse liver (diameter ≥ 0.5 mm), and 
diameter of individual tumor in livers of WT and Nrf2 KO mice by the 
age of 9 months are shown. Arrows indicate tumor nodules. Scale bar, 
10 mm (B). Data represent mean ± standard error of the mean (SEM), 
***
P < 0.001; two-tailed Student t test. 
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I subsequently examined the liver sections of DEN-treated WT and 
Nrf2 KO mice by H&E staining. WT mice showed multiple lesions 
with normal hepatocytes interspaced among the tumor cells, whilst the 
livers from Nrf2 KO mice showed a conserved normal hexagonal 








Figure 4. H&E staining of liver sections from WT and Nrf2 KO 
mice treated with DEN for 9 months. Fifteen-day-old WT and Nrf2 
KO male mice were given a single i.p. dose of DEN. At the age of 9 
months, mice were killed and their liver sections were subjected to 
H&E staining. Abbreviations: T, tumor; CV, central vein; PT, portal 





I further confirmed this result in another set of mouse livers collected at 
14 months after the DEN injection, the duration reported to cause an 
advanced stage of HCC in the DEN-induced HCC mouse model (57). 
Again, the Nrf2 KO mice had no visible tumors in livers even at 14 
months after the DEN injection, while all of the WT mice showed 
















Figure 5. Nrf2 KO mice are resistant to DEN-induced 
hepatocarcinogenesis after 14 months of DEN treatment. (A) WT 
and Nrf2 KO male mice were identified by genotyping. (B) Male mice 
of each genotype (n = 4 mice per genotype) were given DEN at the 
postnatal day 15 and evaluated for tumor burden at the age 14 months. 
Gross morphology of livers (B), the proportion of liver tumor-bearing 
mice, the number of tumors per mouse liver (diameter ≥ 0.5 mm), and 
diameter of individual tumor (C) in livers of WT and Nrf2 KO mice by 
the age of 14 months are shown. Arrows indicate tumor nodules. Scale 





P < 0.05, 
#
P < 0.0001; two-tailed Student's t test. 
 
H&E staining of DEN-treated liver sections revealed hepatic lesions in 
the WT mice but a normal hexagonal liver structure in the Nrf2 KO 
mice without tumors (Fig. 6). Collectively, these results indicate that 
deletion of Nrf2 confers resistance to DEN-induced 


















Figure 6. H&E staining of liver sections from WT and Nrf2 KO 
mice treated with DEN for 14 months. Fifteen-day-old WT and Nrf2 
KO male mice were given a single i.p. dose of DEN. At the age of 14 
months, mice were killed and their liver sections were subjected to 
H&E staining. Abbreviations: T, tumor; CV, central vein; PT, portal 




Nrf2 KO mice show normal expression of hepatic Cyp2e1 but 
lowever levels of phase II detoxifying enzymes 
DEN undergoes initial metabolic conversion to a reactive α-
hydroxydiethylnitrosamine (hydroxylated DEN) by hepatic cytochrome 
P450 (CYP)-dependent monooxygenases, followed by the formation of 
an ethyldiazonium ion intermediate that gives rise to DNA-adducts (59). 
Among CYPs involved in the bioactivation of DEN, cytochrome P450 
2E1 (Cyp2e1) has been considered to be the primary catalyst (59,60). 
Accordingly, I compared the expression levels of Cyp2e1 in 15-day-old 
WT and Nrf2 KO mice at 6 and 48 hours after DEN injection. The 
results show that the hepatic protein levels of Cyp2e1 were not 













Figure 7. Cyp2e1 expression in Nrf2 KO mice is comparable to WT 
mice. Fifteen-day-old mice were intraperitoneally injected with DEN (n 
= 4 mice per genotype) and killed at 6 or 48 hours. Their livers were 
harvested for subsequent experiments. Hepatic Cyp2e1 expression was 
measured by Western blot analysis (left), showing the same level of 
Cyp2e1 expression in the liver of WT and Nrf2 KO mice. 
Densitometric quantification of Cyp2e1 is shown (n = 4 mice per 
genotype; right). Error bars show the SEM. NS: non-significant; two-







Immunohistological (IHC) analysis also revealed that WT and Nrf2 KO 
mice displayed a similar zonation of Cyp2e1 in the centrilobular region 
of the liver where the distribution of Cyp2e1 is mainly confined (61) 













Figure 8. Cyp2e1 expression in Nrf2 KO mice is comparable to WT 
mice. Fifteen-day-old mice were intraperitoneally injected with DEN (n 
= 4 mice per genotype) and killed at 6 or 48 hours. Liver sections of 
both genotypes were immunostained with Cyp2e1 antibody, 
demonstrating the similar areas of Cyp2e1 expression in the 
centrilobular zone (A). DAPI was used to label cellular nuclei. Scale 
bars, 200 µm. (B) Quantification of fluorescent intensity of Cyp2e1 
staining in (A) is shown (n = 4 mice per genotype). Error bars show the 






In addition, the biotransformation of DEN by CYPs also initiates its 
detoxification in the liver by phase II enzymes particularly UDG-
glucuronosyltransferases (Ugts) as the first derivative α-
hydroxydiethylnitrosamine was reported to be prone to glucuronidation, 
permitting it to be excreted in the urine (62). Examination of hepatic 
Ugts by qPCR uncovered that the mRNA levels of Ugt1a1 and Ugt1a6 
after 48 hours of DEN injection at day 15 were higher in WT compared 
to those in Nrf2 KO mice (Fig. 9), suggesting of an even more effective 
toxicant elimination process in WT but not mice deficient in Nrf2. The 
observation is not unexpected, for the transcription of Ugts is largely 














Figure 9. The mRNA levels of Ugt1 phase II detoxifying enzymes 
are higher in WT mice than in Nrf2 KO mice. Fifteen-day-old mice 
were intraperitoneally injected with DEN (n = 4 mice per genotype) 
and killed at 6 or 48 hours after the injection. mRNA levels of phase II 
enzymes Ugt1a1 and Ugt1a6 in the livers were determined by RT-
qPCR (n = 4 mice per genotype). Error bars show the SEM. **P < 0.01, 










Nrf2 KO mice do not exhibit hepatic vascular anomalies. 
The magnitude of the carcinogenicity of DEN could be determined by 
its bioavailability in the liver as well, which is in part affected by the 
degree of blood supply to the hepatocytes. A vascular anomaly, such as 
portosystemic shunt, would decrease the amount of chemicals carried to 
the liver (65). To ascertain whether or not any congenital malformations 
possibly present in the hepatic vasculature of Nrf2 KO mice I used 
could affect the delivery of DEN to the liver, I perfused the livers of 15-
day-old mice with a 0.4% solution of Trypan blue. The perfusion 
showed that the Trypan blue perfused, through the hepatic portal vein, 
penetrated the liver vasculature of Nrf2 KO mice as well as WT mice 













Figure 10. Nrf2 KO mice do not exhibit hepatic shunt. The livers of 
15-day-old mice were perfused with a 0.4% solution of Trypan blue (n 
= 3 mice per genotype). Representative livers following Trypan blue 













In addition, none of the Nrf2 KO mice examined displayed dysplasia in 
the regions surrounding the portal triad (Fig. 11). These findings 
suggest that the genetic disruption of Nrf2 does not provoke noticeable 
hepatic vascular abnormalities in the mice used in the current study.  
 
 
Figure 11. Nrf2 KO mice do not exhibit hepatic anomalies. 
Representatives of H&E-stained liver sections from WT aged 9 months, 
15-day-old Nrf2 KO (n = 9 mice), and 9- (n = 7 mice) and 14- (n = 4 
mice) month-old mice which were used to compare the tumor burden in 








Nrf2 is overexpressed and activated in the hepatomas of DEN-
treated mice 
To understand the mechanisms by which Nrf2 drives tumor progression 
in the liver of DEN-treated mice, I first determined the level of Nrf2 
expressed in hepatomas. As shown in Figure 12A, Nrf2 was detected at 
elevated levels within the DEN-induced liver tumors as compared with 
that in the normal liver tissue of vehicle-treated WT mice. In addition, 
IHC analysis showed an increase in the levels of Nrf2 in the hepatomas 















Figure 12. Nrf2 is overexpressed in hepatomas of DEN-treated WT 
mice. (A) Total lysates from either livers of vehicle (PBS)-treated mice 
or hepatomas of 9-month-old mice given DEN were analyzed by 
immunoblotting. Results show the overexperssion [A; n (tissue) = 3 
from 3 mice] of Nrf2 in tumors. Western blot analysis of Nrf2 protein 
levels (left) and the corresponding quantifications are shown (right). β-
Actin was used as a loading control. (B) Liver sections from DEN-
treated WT mice at the age of 9 months were subjected to Nrf2 staining 
(green). DAPI (dark blue) was used to label cellular nuclei. Data are the 
representative of three different samples. Scale bars, 200 µm (B). Error 
bars show the SEM. 
**
P < 0.01; two-tailed Student's t test. 
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Abbreviations: N, normal; T, tumor. 
 
Furthermore, examining cytosolic and nuclear extracts from livers of 
vehicle-treated mice or hepatomas of 9-month-old mice given DEN by 
Western blotting, I noticed that nuclear accumulation of Nrf2 was 
increased markedly in the tumors (Fig. 13). 
 
Figure 13. Nuclear translocation of Nrf2 is enhanced in hepatomas 
of DEN-treated WT mice. Cytosolic and nuclear factions from either 
livers of vehicle (PBS)-treated mice or hepatomas of 9-month-old mice 
given DEN were analyzed by immunoblotting [n (tissue) = 4 from 4 
mice]. Results show the nuclear accumulation of Nrf2 in tumors. 
Western blot analysis of Nrf2 protein levels (left) and the corresponding 
quantifications are shown (right). GAPDH and lamin B are cytosolic 
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and nuclear markers, respectively. Error bars show the SEM. 
*
P < 0.05; 
two-tailed Student's t test. 
 
The overexpression and increased accumulation of Nrf2 in the nucleus 
were found to be functional as indicated by an increased expression of 
the principal target gene NAD(P)H quinine oxidoreductase 1 (Nqo1) 


















Figure 14. The expression of Nqo1 is enhanced at both protein and 
mRNA levels in hepatomas. Total mRNA or protein samples were 
prepared from tumors, non-tumor adjacent tissue, and vehicle (PBS)-
treated livers of 9-month-old mice, and subjected to Western blotting 
with an antibody against Nqo1 [A; n (tissue) = 3-4 from 3 mice] or RT-
qPCR with specific primers for Nqo1 [D; n (tissue) = 3-4 from 3 mice]. 
Gapdh and α-Tubulin served as internal controls. Error bars show the 
SEM. 
*
P < 0.05, 
**
P < 0.01, 
***
P < 0.001, NS: non-significant; two-








To more precisely examine the transcriptional activity of Nrf2 in the 
hepatomas, ARE-hPAP Tg reporter mice were utilized (54). These mice 
carry a construct of a reporter gene hPAP containing a core sequence 
ARE, which is expressed under the control of Nrf2, hence its 
expression could specifically represent the transcriptional activity of 
Nrf2 (Fig. 15A). Tumors derived from ARE-hPAP mice given DEN 
(Fig. 15B) were subjected to hPAP staining, a reaction in which two 
substrates BCIP and NBT are catalyzed by hPAP to blue-purple 















Figure 15. ARE-hPAP mice were used to measure transcriptional 
activity of Nrf2 in vivo. (A) Strategy for generation of ARE-hPAP Tg 
mice (upper). pA, polyA; ARE: a core sequence ARE. TATA: TATA 
box. hPAP: heat-stable human placental alkaline phosphatase reporter 
gene construct (upper panel). (B) Genotyping of ARE-hPAP mice and 
their control littermates which had been subjected to DEN injection at 






Liver sections from DEN-treated ARE-hPAP mice displayed strong 
hPAP activity in the tumors, reflecting the enhanced transcriptional 
activation of Nrf2 (Fig. 16). Together, these results indicate that Nrf2 is 




















Figure 16. Nrf2 is overactivated in the hepatomas of DEN-treated 
WT mice. Paraffin-embedded liver sections from vehicle (PBS)- or 
DEN-treated ARE-hPAP mice at the age of 10 months were subjected 
to hPAP staining as described in Materials and Methods. Scale bars, 






Nrf2 is required for hepatoma proliferation in the DEN-treated 
mice 
Cell proliferation is a fundamental process required for cancer 
progression (66). Examination of liver sections of mice at 9 months 
after DEN injection revealed that proliferating cells stained with PCNA 
were heavily detected in the hepatomas from WT mice but rarely in 

















Figure 17. Nrf2 promotes cell proliferation in DEN-treated livers. 
Liver sections of WT and Nrf2 KO mice treated with DEN at the age of 





 in the indicated areas were counted and shown 
(n = 3 mice per genotype; right). DAPI was used to label cellular nuclei. 
Scale bars, 200 µm. Error bars show the SEM. 
***
P < 0.001, 
#
P < 
0.0001, NS: non-significant; two-tailed Student t test. Abbreviation: T, 
tumor; N-T, non tumor. DAPI was used to label cellular nuclei.   
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Similarly, Western blot analysis showed an increase in the protein level 
of cyclin D1 (Fig. 18) in WT livers but not in the livers of DEN-treated 
Nrf2 KO mice. These observations suggested that Nrf2 is likely to drive 





















Figure 18. DEN injection results in overexpression of Cyclin D1 in 
livers of WT but not Nrf2 KO mice. Western blot analysis of livers 
from WT and Nrf2 KO mice treated with vehicle [PBS; n (tissue) = 3 
from 3 mice per genotype] or DEN [n (tissue) = 4 from 4 mice per 
genotype] at the age of 9 months showing an elevated level of cyclin 
D1 in the livers of DEN-treated WT mice but not Nrf2 KO littermates. 
GAPDH was used as a loading control. The histogram represents 
quantification of cyclinD1 protein level. Error bars show the SEM. 
***
P 







In an attempt to corroborate this speculation, I examined the short-term 
responses elicited by the DEN administration to WT and Nrf2 KO mice. 
It has been well established that hepatocytes are quiescent in the normal 
liver, but acquire a remarkable capacity to proliferate in response to 
liver damage triggered by carcinogens or inflammatory insults. Not 
only does this mode of proliferation of surviving hepatocytes 
compensate for cell death to allow the maintenance of liver mass but 
also transmit genetic alterations to daughter cells in the favor of liver 
neoplastic progression, followed by dysplasia and later HCC 
development (67). Consistently, it has been firmly believed that 
compensatory hepatocyte proliferation is required for DEN-induced 
carcinogenesis (55,68). I therefore assessed hepatic proliferation in WT 
and Nrf2 KO mice at the age of 15 days following DEN treatment for 
48 hours. BrdU pulse-chase experiment and PCNA staining 
demonstrated the dramatically reduced compensatory proliferative 








Figure 19. Nrf2 deficiency results in impaired compensatory 
proliferation. Liver sections of WT and Nrf2 KO treated with DEN for 
48 hours at the age of 15 days were subjected to BrdU (C; n = 3 mice 
per genotype) or PCNA staining (D, n =3 mice per genotype). The 
number of BrdU
+
 cells per mm
2
 were counted and shown. Scale bars, 
200 µm. Error bars show the SEM. 
***
P < 0.001; two-tailed Student's t 









In addition, I also examined the role of Nrf2 in hepatoma cell 
proliferation. In a colonogenic assay, the silencing of Nrf2 by use of a 
specific small interfering RNA (siRNA) gave rise to decreased colony 
formation of hepatocellular carcinoma HepG2 (Fig. 20A and B) and 
Hep3B (Fig. 20C and D) cells. Collectively, the current study suggests 
that Nrf2 is necessary for cancer progression, presumably through 
stimulation of compensatory proliferation which subsequently enables 









Figure 20. Silencing of Nrf2 reduces colony formation in the 
hepatocellular carcinoma cells. HepG2 (A, B) and Hep3B (C, D) cells 
were transfected with either a control or a specific Nrf2 siRNA. (A, C) 
Total RNA was extracted and analyzed by RT-PCR with Nrf2 sequence-
specific primers, verifying the silencing of Nrf2. GAPDH served as an 
internal control. (B, D) Transfected cells were subsequently subjected 
to colonogenic assays. Representative images were showed on the left 
and histograms (right) display the number of colonies counted (n = 3). 
Error bars show the SEM. 
***
P < 0.001, 
#
P < 0.0001; two-tailed 





Nrf2 enhances the expression of metabolic enzymes required for 
cell proliferation in hepatomas of DEN-treated mice 
For the growth and proliferation of cancer cells, not only energy but 
also the building blocks including nucleotides are required, and they are 
synthesized only from glucose-derived precursors made in pentose 
phosphate pathway (PPP; ref.(69). Thus, it is not surprising to note that 
PPP plays an indispensable role in cancer progression and that PPP-
related enzymes are frequently overexpressed in HCC (70,71). In line 
with this notion, suppressing these enzymes reportedly hampered HCC 
development (69-71). Notably, the expression of some key PPP-related 
enzymes is known to be Nrf2-dependent (72). Thus, I assessed the 
expression levels of the transporter of glucose uptake and 
representative PPP enzymes in the livers of WT and Nrf2 KO mice that 
have been treated with DEN. I first noticed that the level of glucose 
transporter type 1 (Glut1) gene was markedly elevated in the livers of 
















Figure 21. Glut1 is upregulated by Nrf2 in the livers of DEN-
treated mice. RT-qPCR with specific primers were conducted to 
examine the mRNA level of Glut1 in livers of either PBS- (the number 
of tissue samples = 4 from 4 mice per genotype) or DEN-treated (the 
number of tissue samples = 8 from 4 mice per genotype) WT and Nrf2 
KO mice at the age of 9 months. Gapdh served as an internal control. 
Data represent mean ± SEM. 
**







The qPCR assay revealed that the hepatic expression levels of PPP 
metabolic genes encoding glucose-6-phosphate dehydrogenase (G6pd), 
phosphogluconate dehydrogenase (Pgd), transaldolase (Taldo) 1, 
transketolase (Tkt), malic enzyme (Me) 1, isocitrate dehydrogenase 
(Idh1) 1, phosphoribosyl pyrophosphate amidotransferase (Ppat), and 
methylenetetrahydrofolate dehydrogenase (Mthfd) 2 were markedly 
reduced in the DEN-treated Nrf2 KO mice compared with those in WT 
animals subjected to the same treatment (Fig. 22A). Western blot 
analysis also confirmed that there was a profound downregulation of 













Figure 22. Nrf2 modulates the expression of PPP-related enzymes 
in the livers of DEN-treated mice. (A) RT-qPCR with specific primers 
were conducted to examine mRNA levels of indicated metabolic 
enzymes in the livers of vehicle [PBS; n (tissue) = 4 from 4 mice per 
genotype] or DEN-treated [n (tissue) = 8 from 4 mice per genotype] 
WT and Nrf2 KO mice at the age of 9 months. mRNA levels of the 
indicated genes were normalized to that of Gapdh which served as an 
internal control. (B) Immunoblot analysis using liver tissue lysates from 
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9-month-old WT and Nrf2 KO mice given PBS [n (tissue) = 3 from 3 
mice per genotype] or DEN [n (tissue) = 3 from 3 mice per genotype]. 







P < 0.001, 
#
P < 0.0001, NS: non-significant; two-


















Nrf2 undergoes “gain-of-function” mutations during DEN-induced 
hepatocarcinogenesis 
Mutations in the Keap1 binding domain of Nrf2 might prevent its 
degradation which arises from Keap1-binding in the cytoplasm. This 
will result in enhanced nuclear translocation of Nrf2 and subsequently 
its transcriptional activity by binding to ARE (42). Sequencing analysis 
of Nrf2 in human HCC and experimentally induced rat HCC has 
revealed that Nrf2 is commonly mutated in the region encoding the 
domain interacting with Keap1 (50,52). In agreement with this notion, I 
also noticed that Nrf2 was mutated in DEN-induced HCC in mice, 
particularly in pairs of codons encoding amino acid residues 29 (80%) 
and 32 (100%) of its DLG motif (Fig. 23A). The Nrf2 levels in cells 
transfected with constructs expressing either murine or human Nrf2, 
which had been engineered to carry a single mutation in the codon 
encoding the amino acid residue 29, 32, or 80, were higher compared 
with those in cells harboring WT Nrf2 (Fig. 23B and C). These findings 
suggest that mutations in the DLG motif of Nrf2 may account for its 






Figure 23. Mutations of Nrf2 upregulate its protein expression. (A) 
cDNA prepared from livers of vehicle- and DEN-treated mice aged 9 
months was subjected to sequencing analysis. Both nucleotide and 
amino acid substitutions are denoted. N: any nucleotide. (B) Various 
constructs expressing murine Nrf2 carrying indicated single point 
mutations were generated and transfected into HEK293T cells. Total 
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cell lysates were prepared and subjected to Western blot analysis with 
an antibody against Nrf2. Note an increase in the Nrf2 level due to 
these mutations. (C) Western blot analysis shows NRF2 levels in 
HEK293T cells exogenously expressing the indicated mutant forms of 


















I further assembled data from two independent studies of human HCC 
by AMC (56) and TCGA Research Network which have been deposited 
to the cBioPortal for Cancer Genomics (44,45) and analyzed for 
patients’ survival rate. It is noticeable that median survival of HCC 
patients with WT Nrf2 is longer than that of HCC counterparts carrying 
Nrf2 mutations (Fig. 24 and Dataset 1). Together, the data demonstrate 
that the Nrf2 activity in the hepatomas of mice given DEN was 
enhanced likely due to mutations including those in the Keap1 binding 
domain of Nrf2 and the mutations in Nrf2 appeared to be associated 







Figure 24. Mutations in Nrf2 are associated with an inferior 
survival. Kaplan-Meier curves show overall survival of HCC patients 





Nrf2 is a bona fide driver of liver cancer 
Nrf2, the master regulator of cellular redox status is now being put at 
the heart of debate over its dual roles as a tumor suppressor and an 
oncogenic factor (73). Previous studies have demonstrated that 
deficiency of Nrf2 renders animals more vulnerable to various types of 
carcinogens (58,74), while activating Nrf2 may reduce tumor burden 
(75). However, utilization of Nrf2 KO mice allowed me to demonstrate 
the unexpected tumorigenic potential of Nrf2 in the DEN-induced 
murine HCC model. The current findings are in agreement with the 
recently reported observations that activation of Nrf2 promotes the 
progression lung (76), skin (77), and pancreatic cancers (31,78).  
Many different typeas of cancers are known to express 
elaborated levels of ROS (79). It is crucial for cancer cells to maintain 
redox homeostasis as the excessive oxidative stress can also be 
detrimental to their survival (79). This strategy could be achieved by 
programmed expression of antioxidant enzymes that are mainly under 
the control of Nrf2. In line with this speculation, the progression of 
pancreatic cancer was promoted by K-Ras, B-Raf, and Myc oncogenes 
via the Nrf2-triggered antioxidant programs (78). The present study 
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also demonstrates that the expression levels of antioxidant genes 
including Nqo1, heme oxygenase 1 (Hmox1), and glutamate-cysteine 
ligase catalytic subunit (Gclc), whose transcription expression is under 
the tight control of Nrf2 (12), were elevated in the livers of WT mice 




















Figure 25. Nrf2 induces upregulation of hepatic antioxidant gene 
expression in the DEN-treated mice. RT-qPCR with specific primers 
were conducted to examine mRNA levels of indicated Nrf2 target genes 
in the livers of either PBS- (the number of tissue samples = 4 from 4 
mice per genotype) or DEN-treated (the number of tissue samples = 8 
from 4 mice per genotype) WT and Nrf2 KO mice at the age of 9 
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Redox status of cancer cells can also be modulated by the 
reduced form of nicotinamide adenine dinucleotide phosphate 
(NADPH), a reducing equivalent generated in the PPP (69). I noticed 
markedly elevated transcription levels of ARE-regulated PPP enzymes 
in the DEN-treated WT livers, but they were strongly suppressed in the 
livers of Nrf2 KO mice given DEN. In addition to generating NADPH, 
the principal function of PPP is to produce phosphopentoses and 
ribonucleotides required for cell growth and proliferation (69). 
Therefore, the disparity in the extent of these metabolic enzymes in the 
livers of WT and Nrf2 KO mice which have been treated with DEN 
might account for the difference in the tumor burden between these two 
genotypes. In agreement with the current observations, Nrf2 Tg mice 
developed more tumors than their control littermates in a chemically 
induced skin carcinogenesis model due to the overexpression of ARE-
mediated metabolic enzymes that favored the tumor cell growth (77). 
These findings suggest that the oncogenic function of Nrf2 is achieved, 
at least in part, through metabolic reprogramming towards anabolic 
glucose metabolism via the PPP. 
It is noteworthy to mention that in another study, Nrf2 mutant 
mice rather had sporadic congenital intrahepatic shunt, which evoked 
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an altered expression of Cyp2e1 and consequently reduced 
hepatotoxicity of acetaminophen whose bioactivation is also Cyp2e1-
dependent (80). These finding may not be compatible with the current 
study. Although it is challenging to compare these two studies, I 
anticipate that the discrepancy might presumably be due, at least in part, 
to variations in strategies utilized to generate Nrf2 mutant mice. Nrf2 
gene in the above study was disrupted using a positive-negative 
selection targeting vector whose lacZ cassette substitutes for part of 
exon 5 of Nrf2. This results in the deletion of 280 amino acids in 
carboxyl terminus of Nrf2, generating mutant Nrf2 with remaining N-
terminal 301 residues linked to LacZ (8,80). In contrast, I used mice 
with part of exon 4 and all of exon 5 of Nrf2 replaced with a reporter 
gene lacZ in the targeting vector. The replacement depletes the carboxyl 
457 amino acids of Nrf2 and effectively nullifies the functions of Nrf2 
gene (53). 
Nevertheless, remain there still questions that need addressing. 
In this study, the role of Nrf2 as a driver of hepatocarcinogenesis was 
investigated in a mouse model of HCC induced by DEN. Other murine 
HCC models with use of either other hepatocarcinogens such as 
aflatoxin (81) or genetically engineered mice (81) would be needed to 
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further testify these findings. In addition, the observation about the 
oncogenic potential of Nrf2 was made based on a long-term experiment, 
it would be necessary to dissect out the contribution of Nrf2 to HCC in 
the course of hepatocarcinogenesis, and possibly even in the context of 
involvement of other factors. It is also important to look at the 
interaction of Nrf2 with other proteins and factors in liver cancer, 
which is made much easier in the advent of availability of 
bioinformatics and big data.   
In summary, the current findings reveal that Nrf2 serves as a 
key driver in DEN-induced hepatocarcinogenesis. In this disorder, Nrf2 
gains its functions to enhance the expression of genes involved in the 
uptake and redistribution of glucose into PPP in order to support cancer 



















Figure 26. A proposed model for the role of Nrf2 in DEN-induced 
HCC. In DEN-induced murine HCC, Nrf2 is mutated to be 
overactivated. In response to Nrf2 overactivation, genes involving 
utilization and redistribution of glucose into PPP are upregulated to 
support rapid cancer cell proliferation. Abbreviation: DEN, 
diethylnitrosamine; HCC, hepatocellular carcinoma; PPP, pentose 







Nrf2 is also an oncoprotein in other cancers 
The fact that Nrf2/ARE activates the expression of phase II and 
antioxidant enzymes to eliminate excessive electrophiles and ROS and 
favor the survival of normal cells would be logically extended to cancer 
cells (73). Mild oxidative stress plays a role as an important 
intracellular signaling molecule to promote cell proliferation and is 
involved in the maintenance of the oncogenic phenotypes (82), whereas 
ROS accumulated in excess would be a strategy to target cancer cells 
(83). Hence activating Nrf2 is an elegant tactic evolved by cancer cells 
to survive imbalanced redox homeostasis arising from aberrantly high 
metabolism rate (82). It has been reported that endogenous expression 




) and Myc 
(Myc
ERT2
) transcriptionally induces the expression of Nrf2, which then 
results in a favorable intracellular environment for tumor cell survival 
with a lower level of ROS (78). As a consequence, genetic deletion of 
Nrf2 greatly impaired K-Ras
G12D
-induced murine lung and pancreatic 
cancers (78). The protective effects of Nrf2 against oxidative stress are 
applied to proteins, in which Nrf2 allows the cysteine residues in 
protein components of the mRNA translation machinery to maintain the 
reduced status, securing pancreatic cancer cell proliferation and 
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maintenance (31).  A groundbreaking research by Mitsuishi et al. 
revealed that Nrf2 could be hijacked by cancer cells to redistribute 
glucose and glutamine towards the anabolic pathway to meet energy 
demand for rapid growth of cancer cells (72). Mutations in Nrf2 
including amplification and substitutions clustered in a gene region 
coding for amino acids in DLG and ETGE motifs are closely related to 
a poor clinical outcome. Squamous cell lung carcinoma patients with 
these activating genetic alterations in Nrf2 showed a shorter disease-
free survival compared to their cohort with wild-type Nrf2 (42). The 
similar segregation was observed in esophageal squamous cancer (84). 
This suggests the oncogenic potential of “gain-of-function” or activated 
Nrf2 and puts chronically sustained activation of Nrf2 on high alert and 
urgently calls for an approachable intervention in case of cancer with 
overactivated Nrf2. 
 
Future direction: Nrf2 as a target of precision oncology for cancer 
prognosis and treatment 
As Nrf2 appears to serve as an oncogenic factor in cancer, deletion of 
Nrf2 might alleviate cancer progression. However, Nrf2 is required for 
maintenance of physiological redox homeostasis, hence harnessing but 
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not completely deleting Nrf2 might be a better strategy for cancer 
therapy. Moreover, Nrf2 overactivation often occurs as a consequence 
of its mutations by environmental carcinogens rather than amplification 
of its normal gene, so it might be a more fundamental preventive 
strategy to avoid genetoxic insults damaging Nrf2 and/or its regulator 
Keap1. An increasing body of evidence has suggested that the 
oncogenic potential of Nrf2 lies in its “gain-of-function” mutations, 
which heavily cluster in region encoding Keap1 binding motifs DLG 
and ETGE motifs. Therefore, correcting these mutations may delay the 
Nrf2-dependent cancer cell growth and tumor progression. In this 
context, it is interesting to note that replenishment of tumor suppressor 
gene adenomatous polyposis coli (APC), which is frequently mutated 
and inactivated in colorectal cancer, help promote differentiation of 
colon cancer cells and reverse colon cancer in mice (85).  
It is also noticeable that mutations in Nrf2 are related to shorter survival 
time in many types of cancer. Therefore, Nrf2 mutation testing and/or 
profiling Nrf2 should be recommended as part of every single clinical 
practice guideline to categorize patients into groups with or without 
genetic alterations in Nrf2 and subsequently determine precision 






Figure 27. The introduction of Nrf2 in precision cancer therapy. 
Tumor tissues form various types of cancer can be subjected to a series 
of molecular diagnostics including histological and biological analyses 
to evaluate Nrf2 levels as well as the magnitude/frequency of genetic 
alterations. Individuals with genetically altered Nrf2 then would be 
distinguished and grouped to guide the selection of more appropriate 





Strategies to identify genetic alterations of Nrf2 in cancer 
It is now conceivable that tumors are heterogeneous. Within a tumor, 
cancer cells might not be all the same (intratumor heterogeneity) and 
tumors of a given cancer type could be drastically different from patient 
to patient (intertumor heterogeneity) in terms of genetic alterations (86-
88). Intratumor heterogeneity might arise from clonal evolution through 
which selection upon exposure to given therapies gives rise to a pool of 
mutations. Intratumor heterogeneity hence could explain the relapse as 
well as the development of polyclonal resistance in the course of 
treatment in some patients who initially have a good response to a 
given cancer drug. Whilst, the variations among individuals with the 
same type of cancer determine which subgroup would benefit from a 
targeted therapy (86,88). Understanding distinct features of every single 
tumor cell would provide a basis for personalized anticancer therapy in 
the new era of precision medicine (89-91). Current advances in 
characterizing patients and their tumors by use of genomics, proteomics, 
and metabolomics and the availability of large-scale clinical genomic 
database as well as supercomputers used to interpret big data have 
enabled classification of patients and determination of a more precise 
treatment with maximal efficacy and minimal toxicity (89,92). The 
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success of precision cancer medicine rests heavily on the identification 
of validated molecular variations specific to each patient known as 
biomarkers (93).  
     The regularity of genetic alterations in Nrf2 in cancer as well as 
their association with an inferior clinical outcome might suggest that 
this transcriptional factor would serve as a biomarker in precision 
cancer medicine. In this context, profiling Nrf2 would be recommended 
being included in cancer management, encompassing initial diagnosis, 
risk stratification, disease prognosis, predicting responses to treatment, 
and finally deciding more precise medication for corresponding 
individuals. A drop in the cost and advances in high-throughput next-
generation sequencing technology have made characterization of 
genetic aberrations in Nrf2 easier than ever (94,95). Nevertheless, the 
pitfall remains to be addressed here is that Nrf2 profiling has been so 
far conducted on the entire needle biopsies collected through tumor 
removal (42,51), which might not represent the whole tumor genomic 
landscape due to intratumor heterogeneity (88). Single-cell DNA and 
RNA sequencing (SCS) methods developed and revolutionized lately 
(96-98) would be applied to obtain a new powerful approach for 
narrowing understanding any alterations in Nrf2 in every tumor cell 
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rather than in the entire tumor mass (96,97). SCS for characterizing 
Nrf2 would be also extended to circulating tumor cells (CTC), which 
are sloughed from primary tumors and carry even additional acquired 
mutations as a result of exposure to therapeutic treatment in a 
metastatic context (99,100). In addition to CTC, tumor-derived 
circulating-tumor DNA (ctDNA) present in blood or other body fluids 
(101), which has been noticed to well correlate with changes in tumor 
load (102-104), should be encouraged to be subjected to Nrf2 profiling. 
CTC and ctDNA are attractive noninvasive alternatives to tumor 
biopsies, and may reflect real-time tumor burden during the course of 
cancer treatment (105-107).    
 
Chemotherapy to modulate Keap1/Nrf2/ARE axis in Nrf2 mutant-
bearing cancer cells 
A major hurdle toward precision cancer medicine is the development of 
therapeutic agents that are paired with validated biomarkers (90,92). 
The characterization of Nrf2 mutation as a new biomarker in a plethora 
of cancer types might pave the way for further classification of cancer 
into subtypes negative or positive for Nrf2 aberrations, which are 
distinctive in clinical outcomes and apparently response to treatment. In 
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such cases of subclasses addicted to Nrf2, molecules targeting Nrf2 
would be considered of particular interest. Reagents including 
phytochemicals that activate Nrf2 have been long developed in an 
attempt to active Nrf2 in normal cells for chemoprevention (12). On the 
other hand, the increasingly recognized oncogenic roles of 
constitutively activated Nrf2 in transformed or cancerous cells have 
shifted researchers’ attention to the path toward developing Nrf2 
inhibitors. However, unlike thousands of verified Nrf2 activators, only 
a small number of Nrf2 inhibitors have been identified so far (108,109), 
but none of them is available for clinical use currently. A lack in fully 
resolved crystal structure of Nrf2 might be the reason why developing 
Nrf2 inhibitors is in its infancy.  
 
Gene-based therapies to target mutant Nrf2 in cancer cells 
Strategies to attenuate activated Nrf2 
It is noteworthy that sustained activation of Nrf2 lies in its genetic 
alterations, which encompass DNA amplification and somatic point 
mutations, suggesting gene therapy targeting Nrf2. Gene-based 
therapies are basically the introduction of exogenous nucleic acids to 
cancer cells in order to restore the functions of genes that are missing or 
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to halt the expression of tumor-promoting genes (110). RNA 
interference (RNAi) which selectively inhibits translation of mRNA 
transcript of a target gene into a protein has been being broadly 
harnessed for clinical applications and particularly in cases considered 
‘undruggable’ (111,112), could be hold promises for cancer with Nrf2 
amplified. Despite encouraging outcomes from recent clinical trials, 
RNAi therapeutics have some limitations. These include: a need for 
safe and efficient methods to deliver RNAi to the site-of-action without 
posing adverse effects on non-target cells, possible off-target- and 
immunostimulatory effects (113). Thus, RNAi specific to Nrf2 should 
be developed with meticulous attention.  
 
Correction of substitution mutations by programmable nuclease-based 
genome editing technologies 
As a fascinating addition to RNAi therapy, the introduction of 
programmable nucleases-based genome editing technologies have 
paved the way for easier and more efficient deletion or correction of 
genetic aberrations. The principle to achieve genome precisely edited is 
to introduce DNA-double stranded breaks (DSBs) by nucleases at 
genomic locus of interest. Thereafter, either nonhomologous end-
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joining (NHEJ) or homology-directed repair (HDR) in the presence of 
single-stranded oligonucleotides (ssODNs) homologous to the targeted 
region is activated to seal the breaks. NHEJ results in insertion/deletion 
mutations (indel) (114,115), which disrupts the target genes. DSBs 
followed by NHEJ, in consequence, could be introduced to eradicate 
amplified Nrf2 in cancer. HDR allows the exchange of nucleotide 
sequence between targeted DNA strands and ssODN donor templates, 
leading to the introduction of point mutations desired or insertion of 
sequences of choice (114,116). DSBs with ssODNs on the one hand 
allow the insertion of additional mutations to bZIP-Maf in Nrf2, which 
interferes with the interaction of Nrf2 and ARE to attenuate the 
enhanced transcriptional activity of functionally activated Nrf2 in 
cancer. On the other hand, this mechanism also would facilitate the 
correction of activating substitutions in DLG and ETGE motifs of Nrf2, 
turning Keap1-resistant activated Nrf2 to the wild-type one that is 
tightly regulated by Keap1. Currently, four classes of nucleases, 
including three protein-based systems, which are meganucleases, zinc 
finger nucleases (ZFNs) and transcription activator-like effector 
nucleases (TALENs), are available. Because the recognition of specific 
genomic sites by the first three nucleases is based on protein-DNA 
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interactions, different specific nucleases need to be complicatedly 
engineered for different target sequences. The clustered regularly 
interspaced short palindromic repreats (CRISPR)-associated protein 
(Cas) 9 system which has been invented recently is much more flexible 
and ready-to-use as it works on the basis of interaction between an 
engineered short RNA guide and the target DNA site (114,116). Hence, 
the RNA-based CRISPR-cas9 system would be strongly urged to be 
considered as a powerful tool to achieve the desired changes in Nrf2 
including elimination and correction of point mutations. 
 
A need for drug combinations and drug evaluation to precisely target 
Nrf2 for cancer treatment  
A tumor bulk is heterogeneous with a myriad of mutations arising in the 
course of tumor evolution (86,117). Concordantly, in various types of 
cancer, genetic alterations in Nrf2 are temporally accompanied by 
changes of other genes, which might occur at different stages of tumor 
development (118-120). It is apparent to tolerate that behaviors of 
mutated Nrf2 in cancer would be dictated by genetic landscape as well 
as co-coexisting mutations, which is termed epistatic interactions (117). 
Understanding genetic background would thereby provide an elegant 
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platform for optimizing the combination of not only ‘drugs’ targeting 
activated Nrf2 and but also those for other concomitant aberrations to 
achieve the desired therapeutic effects (87).  
     Although Nrf2 could serve as an attractive therapeutic target for 
cancer  treatment, the Nrf2-based aforementioned therapies would not 
be given precisely to the right patients unless the vulnerabilities of live 
patient cancer cells to potential drugs are verified (91). To date, there 
have been many methods developed to obtain the sufficient number of 
patient-derived live cancer cells for ‘drug’ testing. These include 
conditional reprogramming, which involves in the using an enriched 
environment to expand the human tissues, cultivating patient cancer 
cells in a semi-solid extracellular matrix three-dimentional (3D) 
condition to allow formation of organoids (121,122), and enrichment of 
CTCs on an advanced microfluidic chip (123). Various functional 
analyses have been also invented for measuring drug effects on 
patients’ live cancer cells such as utilizing patient-derived xenograft 
(PDX) mouse models (91). This functional testing would be included to 
facilitate the development of therapies targeting Nrf2 and the guidance 





Despite the fact that whether Nrf2 is a tumor suppressor or an oncogene 
has been an unsolved conundrum, it is becoming apparent that Nrf2 
actively secures maintenance of fully malignant cells and therefore 
exacerbating cancer progression cancer progression(31,73). 
Constitutive overactivation of Nrf2 is speculated to regulate metabolic 
reprogramming to meet the anabolic needs for rapid cell 
proliferation(30,72), and to create a favorable microenvironment with 
less oxidative stress for cancer cell growth via the overexpression of 
phase II-detoxifying and antioxidant enzymes(78). These tumorigenic 
potentials of Nrf2 lie in its sustained activation in cancer, which is 
speculated to arise from two ‘hot-spots’ gain-of-function mutations 
located in the DLG and ETGE motifs in the Neh2 domain(124). As 
these aberrations of Nrf2 are so ubiquitous and involves in behavior and 
vulnerability to chemotherapies in a medley of cancer types, they could 
be supposed to be an attractive target for precision cancer therapy. 
However, it still remains questioned to what extent these genetic 
changes and hot-spot mutations of Nrf2 contributes to cancer 
progression. For targeting Nrf2, it is critical to profile the genotype of 
this transcription factor in every single cell from either tumor bulks or 
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CTCs, and not to mention, to consider the not only Nrf2 but the entire 






















1. Miller EC, Miller JA. Mechanisms of chemical carcinogenesis. 
Cancer 1981;47(5 Suppl):1055-64. 
2. Miller JA. Carcinogenesis by chemicals: an overview--G. H. A. 
Clowes memorial lecture. Cancer Res 1970;30(3):559-76. 
3. Benson AM, Batzinger RP, Ou SY, Bueding E, Cha YN, Talalay 
P. Elevation of hepatic glutathione S-transferase activities and 
protection against mutagenic metabolites of benzo(a)pyrene by 
dietary antioxidants. Cancer Res 1978;38(12):4486-95. 
4. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, 
Rodriguez L, et al. Phase IIa clinical trial of curcumin for the 
prevention of colorectal neoplasia. Cancer Prev Res (Phila) 
2011;4(3):354-64. 
5. Rushmore TH, Morton MR, Pickett CB. The antioxidant 
responsive element. Activation by oxidative stress and 
identification of the DNA consensus sequence required for 
functional activity. J Biol Chem 1991;266(18):11632-9. 
6. Xie T, Belinsky M, Xu Y, Jaiswal AK. ARE- and TRE-mediated 
regulation of gene expression. Response to xenobiotics and 
antioxidants. J Biol Chem 1995;270(12):6894-900. 
7. Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-
related factor 2 (Nrf2), a NF-E2-like basic leucine zipper 
transcriptional activator that binds to the tandem NF-E2/AP1 
repeat of the beta-globin locus control region. Proc Natl Acad 
90 
 
Sci U S A 1994;91(21):9926-30. 
8. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. 
An Nrf2/small Maf heterodimer mediates the induction of phase 
II detoxifying enzyme genes through antioxidant response 
elements. Biochem Biophys Res Commun 1997;236(2):313-22. 
9. Xu Z, Wang S, Ji H, Zhang Z, Chen J, Tan Y, et al. Broccoli 
sprout extract prevents diabetic cardiomyopathy via Nrf2 
activation in db/db T2DM mice. Sci Rep 2016;6:30252. 
10. Howden R. Nrf2 and cardiovascular defense. Oxid Med Cell 
Longev 2013;2013:104308. 
11. Xiong W, MacColl Garfinkel AE, Li Y, Benowitz LI, Cepko CL. 
NRF2 promotes neuronal survival in neurodegeneration and 
acute nerve damage. J Clin Invest 2015;125(4):1433-45. 
12. Surh YJ. Cancer chemoprevention with dietary phytochemicals. 
Nat Rev Cancer 2003;3(10):768-80. 
13. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 
signaling pathway in cancer. Genes Dev 2013;27(20):2179-91. 
14. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, 
et al. Keap1 represses nuclear activation of antioxidant 
responsive elements by Nrf2 through binding to the amino-
terminal Neh2 domain. Genes Dev 1999;13(1):76-86. 
15. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M. 
Keap1 recruits Neh2 through binding to ETGE and DLG 
motifs: characterization of the two-site molecular recognition 
91 
 
model. Mol Cell Biol 2006;26(8):2887-900. 
16. Nioi P, Nguyen T, Sherratt PJ, Pickett CB. The carboxy-terminal 
Neh3 domain of Nrf2 is required for transcriptional activation. 
Mol Cell Biol 2005;25(24):10895-906. 
17. Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A, 
Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a 
CREB binding protein, and synergistically activate transcription. 
Genes Cells 2001;6(10):857-68. 
18. Salazar M, Rojo AI, Velasco D, de Sagarra RM, Cuadrado A. 
Glycogen synthase kinase-3beta inhibits the xenobiotic and 
antioxidant cell response by direct phosphorylation and nuclear 
exclusion of the transcription factor Nrf2. J Biol Chem 
2006;281(21):14841-51. 
19. McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. 
Redox-regulated turnover of Nrf2 is determined by at least two 
separate protein domains, the redox-sensitive Neh2 degron and 
the redox-insensitive Neh6 degron. J Biol Chem 
2004;279(30):31556-67. 
20. Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, 
Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase 
kinase 3-dependent degradation of the Nrf2 transcription factor 
in a Keap1-independent manner. Mol Cell Biol 
2011;31(6):1121-33. 
21. Wang H, Liu K, Geng M, Gao P, Wu X, Hai Y, et al. RXRalpha 
inhibits the NRF2-ARE signaling pathway through a direct 




22. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, 
Wakabayashi N, Katoh Y, et al. Direct evidence that sulfhydryl 
groups of Keap1 are the sensors regulating induction of phase 2 
enzymes that protect against carcinogens and oxidants. Proc 
Natl Acad Sci U S A 2002;99(18):11908-13. 
23. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang 
MI, Kobayashi A, Yamamoto M, et al. Protection against 
electrophile and oxidant stress by induction of the phase 2 
response: fate of cysteines of the Keap1 sensor modified by 
inducers. Proc Natl Acad Sci U S A 2004;101(7):2040-5. 
24. Zipper LM, Mulcahy RT. The Keap1 BTB/POZ dimerization 
function is required to sequester Nrf2 in cytoplasm. J Biol 
Chem 2002;277(39):36544-52. 
25. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The 
Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-
based E3 ligase: oxidative stress sensing by a Cul3-Keap1 
ligase. Mol Cell Biol 2004;24(19):8477-86. 
26. Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant 
transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 
ligase. Mol Cell Biol 2005;25(1):162-71. 
27. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo 
MO. Antioxidants accelerate lung cancer progression in mice. 
Sci Transl Med 2014;6(221):221ra15. 
28. Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson 
C, et al. Antioxidants can increase melanoma metastasis in mice. 
Sci Transl Med 2015;7(308):308re8. 
93 
 
29. Wang H, Liu X, Long M, Huang Y, Zhang L, Zhang R, et al. 
NRF2 activation by antioxidant antidiabetic agents accelerates 
tumor metastasis. Sci Transl Med 2016;8(334):334ra51. 
30. DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, 
et al. NRF2 regulates serine biosynthesis in non-small cell lung 
cancer. Nat Genet 2015;47(12):1475-81. 
31. Chio, II, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, 
Palm W, et al. NRF2 Promotes Tumor Maintenance by 
Modulating mRNA Translation in Pancreatic Cancer. Cell 
2016;166(4):963-76 . 
32. Yang C, Tan YX, Yang GZ, Zhang J, Pan YF, Liu C, et al. 
Gankyrin has an antioxidative role through the feedback 
regulation of Nrf2 in hepatocellular carcinoma. J Exp Med 
2016;213(5):859-75. 
33. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, et al. 
High levels of Nrf2 determine chemoresistance in type II 
endometrial cancer. Cancer Res 2010;70(13):5486-96. 
34. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, 
Sanisetty S, Grammatikos AP, et al. Keap1 mutations and Nrf2 
pathway activation in epithelial ovarian cancer. Cancer Res 
2011;71(15):5081-9. 
35. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: 
permanent activation of an adaptive response in cancer. Trends 
Biochem Sci 2009;34(4):176-88. 
36. Ikeda H, Nishi S, Sakai M. Transcription factor Nrf2/MafK 
regulates rat placental glutathione S-transferase gene during 
hepatocarcinogenesis. Biochem J 2004;380(Pt 2):515-21. 
94 
 
37. Stacy DR, Ely K, Massion PP, Yarbrough WG, Hallahan DE, 
Sekhar KR, et al. Increased expression of nuclear factor E2 p45-
related factor 2 (NRF2) in head and neck squamous cell 
carcinomas. Head Neck 2006;28(9):813-8. 
38. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, et al. 
Nrf2 enhances resistance of cancer cells to chemotherapeutic 
drugs, the dark side of Nrf2. Carcinogenesis 2008;29(6):1235-
43. 
39. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, 
Ohtsuji M, et al. Structural basis for defects of Keap1 activity 
provoked by its point mutations in lung cancer. Mol Cell 
2006;21(5):689-700. 
40. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque 
MO, et al. Dysfunctional KEAP1-NRF2 interaction in non-
small-cell lung cancer. PLoS Med 2006;3(10):e420. 
41. Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hypermethylation 
of the Keap1 gene in human lung cancer cell lines and lung 
cancer tissues. Biochem Biophys Res Commun 
2008;373(1):151-4. 
42. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, et 
al. Cancer related mutations in NRF2 impair its recognition by 
Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad 
Sci U S A 2008;105(36):13568-73. 
43. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, et al. 
Oncogenic NRF2 mutations in squamous cell carcinomas of 
oesophagus and skin. J Pathol 2010;220(4):446-51. 
95 
 
44. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, 
et al. The cBio cancer genomics portal: an open platform for 
exploring multidimensional cancer genomics data. Cancer 
Discov 2012;2(5):401-4. 
45. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, 
et al. Integrative analysis of complex cancer genomics and 
clinical profiles using the cBioPortal. Sci Signal 
2013;6(269):pl1. 
46. Fukutomi T, Takagi K, Mizushima T, Ohuchi N, Yamamoto M. 
Kinetic, thermodynamic, and structural characterizations of the 
association between Nrf2-DLGex degron and Keap1. Mol Cell 
Biol 2014;34(5):832-46. 
47. Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A, 
Hayes JD. Nrf2 is controlled by two distinct beta-TrCP 
recognition motifs in its Neh6 domain, one of which can be 
modulated by GSK-3 activity. Oncogene 2013;32(32):3765-81. 
48. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic 
Landscape and Biomarkers of Hepatocellular Carcinoma. 
Gastroenterology 2015;149(5):1226-39. 
49. Laursen L. A preventable cancer. Nature 2014;516(7529):S2-3. 
50. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, 
Maad IB, et al. Integrated analysis of somatic mutations and 
focal copy-number changes identifies key genes and pathways 
in hepatocellular carcinoma. Nat Genet 2012;44(6):694-8. 
51. Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi 
Y, et al. Whole-genome mutational landscape and 
characterization of noncoding and structural mutations in liver 
96 
 
cancer. Nat Genet 2016;48(5):500-9. 
52. Zavattari P, Perra A, Menegon S, Kowalik MA, Petrelli A, 
Angioni MM, et al. Nrf2, but not beta-catenin, mutation 
represents an early event in rat hepatocarcinogenesis. 
Hepatology 2015;62(3):851-62. 
53. Chan K, Lu R, Chang JC, Kan YW. NRF2, a member of the 
NFE2 family of transcription factors, is not essential for murine 
erythropoiesis, growth, and development. Proc Natl Acad Sci U 
S A 1996;93(24):13943-8. 
54. Johnson DA, Andrews GK, Xu W, Johnson JA. Activation of 
the antioxidant response element in primary cortical neuronal 
cultures derived from transgenic reporter mice. J Neurochem 
2002;81(6):1233-41. 
55. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy 
AM, et al. Gender disparity in liver cancer due to sex 
differences in MyD88-dependent IL-6 production. Science 
2007;317(5834):121-4. 
56. Ahn SM, Jang SJ, Shim JH, Kim D, Hong SM, Sung CO, et al. 
Genomic portrait of resectable hepatocellular carcinomas: 
implications of RB1 and FGF19 aberrations for patient 
stratification. Hepatology 2014;60(6):1972-82. 
57. Hacker HJ, Mtiro H, Bannasch P, Vesselinovitch SD. 
Histochemical profile of mouse hepatocellular adenomas and 
carcinomas induced by a single dose of diethylnitrosamine. 
Cancer Res 1991;51(7):1952-8. 
97 
 
58. Becks L, Prince M, Burson H, Christophe C, Broadway M, Itoh 
K, et al. Aggressive mammary carcinoma progression in Nrf2 
knockout mice treated with 7,12-dimethylbenz[a]anthracene. 
BMC Cancer 2010;10:540. 
59. Verna L, Whysner J, Williams GM. N-nitrosodiethylamine 
mechanistic data and risk assessment: bioactivation, DNA-
adduct formation, mutagenicity, and tumor initiation. Pharmacol 
Ther 1996;71(1-2):57-81. 
60. Kang JS, Wanibuchi H, Morimura K, Gonzalez FJ, Fukushima 
S. Role of CYP2E1 in diethylnitrosamine-induced 
hepatocarcinogenesis in vivo. Cancer Res 2007;67(23):11141-6. 
61. Oinonen T, Lindros KO. Zonation of hepatic cytochrome P-450 
expression and regulation. Biochem J 1998;329 ( Pt 1):17-35. 
62. Wiench K, Frei E, Schroth P, Wiessler M. 1-C-glucuronidation 
of N-nitrosodiethylamine and N-nitrosomethyl-n-pentylamine in 
vivo and in primary hepatocytes from rats pretreated with 
inducers. Carcinogenesis 1992;13(5):867-72. 
63. Buckley DB, Klaassen CD. Induction of mouse UDP-
glucuronosyltransferase mRNA expression in liver and intestine 
by activators of aryl-hydrocarbon receptor, constitutive 
androstane receptor, pregnane X receptor, peroxisome 
proliferator-activated receptor alpha, and nuclear factor 
erythroid 2-related factor 2. Drug Metab Dispos 
2009;37(4):847-56. 
64. Yueh MF, Tukey RH. Nrf2-Keap1 signaling pathway regulates 
98 
 
human UGT1A1 expression in vitro and in transgenic UGT1 
mice. J Biol Chem 2007;282(12):8749-58. 
65. Berent AC, Tobias KM. Portosystemic vascular anomalies. Vet 
Clin North Am Small Anim Pract 2009;39(3):513-41. 
66. Hanahan D, Weinberg RA. Hallmarks of cancer: the next 
generation. Cell 2011;144(5):646-74. 
67. Fausto N. Mouse liver tumorigenesis: models, mechanisms, and 
relevance to human disease. Semin Liver Dis 1999;19(3):243-
52. 
68. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta 
couples hepatocyte death to cytokine-driven compensatory 
proliferation that promotes chemical hepatocarcinogenesis. Cell 
2005;121(7):977-90. 
69. Patra KC, Hay N. The pentose phosphate pathway and cancer. 
Trends Biochem Sci 2014;39(8):347-54. 
70. Wang C, Guo K, Gao D, Kang X, Jiang K, Li Y, et al. 
Identification of transaldolase as a novel serum biomarker for 
hepatocellular carcinoma metastasis using xenografted mouse 
model and clinic samples. Cancer Lett 2011;313(2):154-66. 
71. Xu IM, Lai RK, Lin SH, Tse AP, Chiu DK, Koh HY, et al. 
Transketolase counteracts oxidative stress to drive cancer 
development. Proc Natl Acad Sci U S A 2016;113(6):E725-34. 
72. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, 
Aburatani H, et al. Nrf2 redirects glucose and glutamine into 




73. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and 
the importance of context. Nat Rev Cancer 2012;12(8):564-71. 
74. Khor TO, Huang MT, Prawan A, Liu Y, Hao X, Yu S, et al. 
Increased susceptibility of Nrf2 knockout mice to colitis-
associated colorectal cancer. Cancer Prev Res (Phila) 
2008;1(3):187-91. 
75. Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor TO, et al. 
Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin 
tumorigenesis in C57BL/6 mice by sulforaphane is mediated by 
nuclear factor E2-related factor 2. Cancer Res 
2006;66(16):8293-6. 
76. Satoh H, Moriguchi T, Takai J, Ebina M, Yamamoto M. Nrf2 
prevents initiation but accelerates progression through the Kras 
signaling pathway during lung carcinogenesis. Cancer Res 
2013;73(13):4158-68. 
77. Rolfs F, Huber M, Kuehne A, Kramer S, Haertel E, Muzumdar 
S, et al. Nrf2 Activation Promotes Keratinocyte Survival during 
Early Skin Carcinogenesis via Metabolic Alterations. Cancer 
Res 2015;75(22):4817-29. 
78. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, 
Frese K, et al. Oncogene-induced Nrf2 transcription promotes 
ROS detoxification and tumorigenesis. Nature 
2011;475(7354):106-9. 
79. Trachootham D, Alexandre J, Huang P. Targeting cancer cells 
by ROS-mediated mechanisms: a radical therapeutic approach? 
Nat Rev Drug Discov 2009;8(7):579-91. 
80. Skoko JJ, Wakabayashi N, Noda K, Kimura S, Tobita K, 
100 
 
Shigemura N, et al. Loss of Nrf2 in mice evokes a congenital 
intrahepatic shunt that alters hepatic oxygen and protein 
expression gradients and toxicity. Toxicol Sci 2014;141(1):112-
9. 
81. Heindryckx F, Colle I, Van Vlierberghe H. Experimental mouse 
models for hepatocellular carcinoma research. Int J Exp Pathol 
2009;90(4):367-86. 
82. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell 
metabolism. Nat Rev Cancer 2011;11(2):85-95. 
83. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as 
an anticancer strategy. Nat Rev Drug Discov 2013;12(12):931-
47. 
84. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, 
Aoyagi K, et al. NRF2 mutation confers malignant potential and 
resistance to chemoradiation therapy in advanced esophageal 
squamous cancer. Neoplasia 2011;13(9):864-73. 
85. Dow LE, O'Rourke KP, Simon J, Tschaharganeh DF, van Es JH, 
Clevers H, et al. Apc Restoration Promotes Cellular 
Differentiation and Reestablishes Crypt Homeostasis in 
Colorectal Cancer. Cell 2015;161(7):1539-52. 
86. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes 
and consequences of genetic heterogeneity in cancer evolution. 
Nature 2013;501(7467):338-45. 
87. Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, 
Borowski C, et al. Toward understanding and exploiting tumor 
heterogeneity. Nat Med 2015;21(8):846-53. 
101 
 
88. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour 
heterogeneity in the clinic. Nature 2013;501(7467):355-64. 
89. Collins FS, Varmus H. A new initiative on precision medicine. 
N Engl J Med 2015;372(9):793-5. 
90. Vargas AJ, Harris CC. Biomarker development in the precision 
medicine era: lung cancer as a case study. Nat Rev Cancer 
2016;16(8):525-37. 
91. Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision 
medicine for cancer with next-generation functional diagnostics. 
Nat Rev Cancer 2015;15(12):747-56. 
92. Collins DC, Sundar R, Lim JS, Yap TA. Towards Precision 
Medicine in the Clinic: From Biomarker Discovery to Novel 
Therapeutics. Trends Pharmacol Sci 2017;38(1):25-40. 
93. Lyman GH, Moses HL. Biomarker Tests for Molecularly 
Targeted Therapies--The Key to Unlocking Precision Medicine. 
N Engl J Med 2016;375(1):4-6. 
94. Park JY, Kricka LJ, Fortina P. Next-generation sequencing in 
the clinic. Nat Biotechnol 2013;31(11):990-2. 
95. Goodwin S, McPherson JD, McCombie WR. Coming of age: 
ten years of next-generation sequencing technologies. Nat Rev 
Genet 2016;17(6):333-51. 
96. Gawad C, Koh W, Quake SR. Single-cell genome sequencing: 
current state of the science. Nat Rev Genet 2016;17(3):175-88. 
97. Zhang X, Marjani SL, Hu Z, Weissman SM, Pan X, Wu S. 
Single-Cell Sequencing for Precise Cancer Research: Progress 
and Prospects. Cancer Res 2016;76(6):1305-12. 
102 
 
98. Navin NE. The first five years of single-cell cancer genomics 
and beyond. Genome Res 2015;25(10):1499-507. 
99. Navin NE. Delineating cancer evolution with single-cell 
sequencing. Sci Transl Med 2015;7(296):296fs29. 
100. Shaw JA, Guttery DS, Hills A, Fernandez-Garcia D, Page K, 
Rosales BM, et al. Mutation Analysis of Cell-Free DNA and 
Single Circulating Tumor Cells in Metastatic Breast Cancer 
Patients with High Circulating Tumor Cell Counts. Clin Cancer 
Res 2017;23(1):88-96. 
101. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid 
biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin 
Oncol 2013;10(8):472-84. 
102. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin 
SF, et al. Analysis of circulating tumor DNA to monitor 
metastatic breast cancer. N Engl J Med 2013;368(13):1199-209. 
103. Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-
Crapez E, Rolet F, et al. Clinical validation of the detection of 
KRAS and BRAF mutations from circulating tumor DNA. Nat 
Med 2014;20(4):430-5. 
104. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin 
LA, et al. An ultrasensitive method for quantitating circulating 
tumor DNA with broad patient coverage. Nat Med 
2014;20(5):548-54. 
105. Alix-Panabieres C, Pantel K. Clinical Applications of 
Circulating Tumor Cells and Circulating Tumor DNA as Liquid 
Biopsy. Cancer Discov 2016;6(5):479-91. 
103 
 
106. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal 
N, et al. Detection of circulating tumor DNA in early- and late-
stage human malignancies. Sci Transl Med 
2014;6(224):224ra24. 
107. Alix-Panabieres C, Pantel K. Real-time liquid biopsy: 
circulating tumor cells versus circulating tumor DNA. Ann 
Transl Med 2013;1(2):18. 
108. Menegon S, Columbano A, Giordano S. The Dual Roles of 
NRF2 in Cancer. Trends Mol Med 2016;22(7):578-93. 
109. No JH, Kim YB, Song YS. Targeting nrf2 signaling to combat 
chemoresistance. J Cancer Prev 2014;19(2):111-7. 
110. Kay MA. State-of-the-art gene-based therapies: the road ahead. 
Nat Rev Genet 2011;12(5):316-28. 
111. Zuckerman JE, Davis ME. Clinical experiences with 
systemically administered siRNA-based therapeutics in cancer. 
Nat Rev Drug Discov 2015;14(12):843-56. 
112. Wittrup A, Lieberman J. Knocking down disease: a progress 
report on siRNA therapeutics. Nat Rev Genet 2015;16(9):543-
52. 
113. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-
target effects for target identification and therapeutic application. 
Nat Rev Drug Discov 2010;9(1):57-67. 
114. Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE. 
Cornerstones of CRISPR-Cas in drug discovery and therapy. 
Nat Rev Drug Discov 2017;16(2):89-100. 
115. Dominguez AA, Lim WA, Qi LS. Beyond editing: repurposing 
CRISPR-Cas9 for precision genome regulation and 
104 
 
interrogation. Nat Rev Mol Cell Biol 2016;17(1):5-15. 
116. Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: 
prospects and challenges. Nat Med 2015;21(2):121-31. 
117. McGranahan N, Swanton C. Biological and therapeutic impact 
of intratumor heterogeneity in cancer evolution. Cancer Cell 
2015;27(1):15-26. 
118. Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, 
Kato M, et al. Trans-ancestry mutational landscape of 
hepatocellular carcinoma genomes. Nat Genet 
2014;46(12):1267-73. 
119. Comprehensive molecular profiling of lung adenocarcinoma. 
Nature 2014;511(7511):543-50. 
120. Riaz N, Morris LG, Lee W, Chan TA. Unraveling the molecular 
genetics of head and neck cancer through genome-wide 
approaches. Genes Dis 2014;1(1):75-86. 
121. Boj SF, Hwang CI, Baker LA, Chio, II, Engle DD, Corbo V, et 
al. Organoid models of human and mouse ductal pancreatic 
cancer. Cell 2015;160(1-2):324-38. 
122. Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model 
of human development and disease. Nat Cell Biol 
2016;18(3):246-54. 
123. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson 
MC, et al. Cancer therapy. Ex vivo culture of circulating breast 
tumor cells for individualized testing of drug susceptibility. 
Science 2014;345(6193):216-20. 
124. Goldstein LD, Lee J, Gnad F, Klijn C, Schaub A, Reeder J, et al. 
105 
 
Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 

























Table 1: The sequences of primers used for genotyping 
Gene symbol Primer name Primer sequence 
Nrf2 WT  
gNrf2-F:         
gNrf2-R:                                
5’-GGA ATG GAA AAT AGC TCC TGC C-3’ 
5’-GCC TGA GAG CTG TAG GCC C-3’ 




5’-CTA GAG TCA CAG TGA CTT GGC AAA-3’ 











                                            
*
 F: Forward 
  R: Reverse 
  g: genomic 
  h: human 




Table 2: The sequences of primers used for qPCR 
Gene symbol Primer name Primer sequence 
Gapdh 
m Gapdh -F 
m Gapdh -R 
5’-GCC CTT GAG CTA GGA CTG G-3’  




5’-GGC CCA TTC AGA GAA GAC AT-3’  




5’-CCA CTC CCT GTG TTT CCT TT-3’  




5’-GCA GCA TAT CTG AGG CAA GA-3’ 




5’-GCT GCC AGG TTC TAG TCT CC-3’ 
5’-AGT GTC CGT GTC TTC AGC AG-3’ 
G6pdx 
m G6pdx -F 
m G6pdx -R 
5’-AGG AAG TGG TCA AGG ACA CC-3’ 




5’-CGT AAG GCC CTC TAT GCT TC-3’ 




5’-CAG ACC AGT GAC TCG GAG AA-3’ 




5’- TAT GGG TGG TCA CTG CTG TT-3’ 






5’-GCA TGC CAG CAG TAC AGT TT-3’ 
5’-GAT GCG CTC TCC ATC AGT TA-3’ 
Idh1 
m Idh1 -F 
m Idh1-R 
5’-AAG CTA TGA AGT CCG AGG GA-3’ 




5’- ATG GAA ATC GTC CTC TCT GC-3’ 




5’-CGG CAC TCC CTT ACT CTC TC-3’ 















Table 3: The primers used for identifying mutations in Nrf2 
Gene symbol Primer name Primer sequence 
Nrf2 
m gNrf2-F 
m gNrf2-R  
5’-CTC ACA AAG TCC TCC CTG TGA T-3’ 




Table 4: The sequences of primers used for constructing plasmids 
and site-directed mutagenesis study 

















5’-TGG AGG CAA GAC ATA GGT CTT 
GGA GTA AGT CGA-3’ 
5’-TCG ACT TAC TCC AAG ACC TAT 




5’-GAC ATA GAT CTT GGA GAA AGT 
CGA GAA GTG TTT-3’ 
5’-AAA CAC TTC TCG ACT TTC TCC 




5’-CAA CTG GAT GAA GAA GCA GGA 
GAA TTC CTC CCA-3’ 
5’-TGG GAG GAA TTC TCC TGC TTC 
TTC ATC CAG TTG-3’ 







m Nrf2 stop codon-R 
CCG CCA GGA CTA-3’ 
5’-TAG TCC TGG CGG TGG CTA CTC 




5’-TGG AGG CAA GAT ATA GGT CTT 
GGA GTA AGT CGA-3’ 
5’-TCG ACT TAC TCC AAG ACC TAT 




5’-CAA CTA GAT GAA GAG CCA GGT 
GAA TTT CTC CCA-3’ 
5’-TGG GAG AAA TTC ACC TGG CTC 














Dataset S1. HCC patients with Nrf2 mutations. Abbreviations: TCGA, The Cancer 





ABSTRACT IN KOREAN (국문초록) 
Diethylnitrosamine  으로 유도된 간암 발생과정 에서 Nrf2의 역할 
 
암으로 인한 사망 중 가장 큰 원인인 간암은 표현형 혹은 유
전적으로 서로 다른 형질 (heterogeneous)을 갖는 것으로 알려
져 있다. Nrf2는 세포내 다양한 스트레스에 의해 활성화 되어 
항산화, 해독화 효소들의 발현을 촉진시키는 전사인자로 생체
내 방어 기전에 관여하며 간암의 화학적 암예방의 주요한 표
적 단백질로 보고되고 있다. 그러나 Nrf2 결핍마우스에 
cytochrome p450 2E1 (Cyp2e1)에 의한 DEN의 대사적 활성화의 
약화나 간의 혈관구조 (hepatic vasculature)의 손상 없이 
diethylnitrosamine (DEN)에 의해 유도되는 간암 발생에 있어서 
저항기전을 보여 오히려 암화를 촉진시켰다. 본 연구에서는 
DEN에 의해 유도되는 간암 발생 기전에 있어서 Nrf2의 역할
과, Nrf2의 활성이 어떻게 조절 될 수 있는지 알아보고자 하였
다. 간의 종양에서 Nrf2의 단백질의 발현과 핵내 이동, Nrf2의 
전사적 활성이 증가되어 있으며, DEN에 의해 유도되는 Nrf2의 
과발현이 간암세포의 성장속도를 증가시켰다. 그 분자적 기전
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을 살펴본 결과 DEN 처리시 Nrf2의 유전자 파열/파괴 (genetic 
disruption)이 글루코오스 흡수 (glucose uptake)와 펜토오스 인산
경로 (pentose phosphate pathway)에 관여하는 효소들의 운반체 
(transporter)의 발현을 감소시킴으로 간암으로의 진행이 약화되
었다. 또한 세포내 잘 알려진 Nrf2 억제 단백질인 Keap1과의 
결합 도메인의 변형(alteration)이 Nrf2의 과도한 활성화 현상을 
야기시켰으며, Nrf2의 활성화된 돌연변이주를 지닌 간암 환자
는 그렇지 않은 환자에 비해 전체 생존기간 (overall survival)이 
짧음을 확인 할 수 있었다. 결론적으로 Nrf2는 간암발생을 촉
진시키며 향후 항암제 치료의 목표물로 기능할 수 있음을 제
시 할 수 있다. 
 
Keywords: Nrf2, diethylnitrosamine, hepatocarcinogenesis, 
antioxidant response elements, pentose phosphate pathway. 
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